• Capsaicin: A Dual-Target Research Strategy

  2026-08-22

  Capsaicin is more than a TRPV1 agonist: it also provides a mechanistically defined route to study reversible KDM1A/LSD1 inhibition. This article connects channel pharmacology, epigenetic assays, and gastric cancer phenotypes into a practical framework for selecting controls and interpreting results.

• HLY78: Practical Wnt/β-Catenin Assay Design

  2026-08-21

  Learn how HLY78 (SKU C5433) can support controlled Wnt/β-catenin pathway experiments while preventing common viability-assay misinterpretations. This scenario-based guide covers mechanism, assay compatibility, stock preparation, data analysis, and practical vendor selection.

• TRPV1/TRPA1 Control of TSLP in Nasal Epithelium

  2026-08-21

  The reference study shows that TRPV1 and TRPA1 are functionally expressed in nasal epithelial cells and connect environmental sensing to TSLP production through calcium-dependent NFAT signaling. Its combined imaging, pharmacological, genetic, and chelation experiments provide a useful framework for investigating epithelial contributions to upper-airway inflammation.

• SAR131675: A Causal Map of VEGFR-3 Biology

  2026-08-20

  SAR131675 is a selective VEGFR-3 inhibitor for dissecting lymphangiogenesis, angiogenesis, and VEGFC-dependent liver inflammation. This article translates its pharmacology into a causal assay strategy informed by a recent hepatic fibrosis study.

• HyperFluor 488 Goat Anti-Mouse IgG for NET Imaging

  2026-08-20

  Build sensitive, cross-platform assays for psoriasis-related NETosis and IL-36R signaling with one affinity-purified fluorescent secondary. The same reagent can connect microscopy, flow cytometry, and western blot validation while keeping assay controls and tissue-background risks visible.

• Recombinant Mouse IFN-γ in MASH-HCC Assays

  2026-08-19

  Use Recombinant Mouse IFN-γ as a controlled immune-pressure variable in bile acid, MHC-I, and tumor-cell antigenicity experiments. This workflow separates cytokine responsiveness from the GPR120–bile acid–NLRC5 mechanism and adds practical controls for reproducible immunometabolic research.

• AI-10-49: A Target-Engagement Guide for inv(16) AML

  2026-08-18

  AI-10-49 is a CBFβ-SMMHC inhibitor that enables a layered approach to inv(16) acute myeloid leukemia research. This guide connects target engagement, RUNX1 chromatin redistribution, transcriptional recovery, and leukemia phenotypes to practical assay decisions.

• iRhom2 in Olfaction: Receptor Regulation and Adaptation

  2026-08-18

  Azzopardi and colleagues identify iRhom2 as a previously underrecognized regulator in olfactory sensory neurons and link it to odorant receptor expression and activity-dependent adaptation through the ADAM17 pathway. The study combines mouse genetics, transcriptomics, in situ analysis, and a receptor activation model to propose a feedback mechanism in which odor exposure suppresses iRhom2 expression.

• A-1331852: Interpreting BCL-XL Dependence

  2026-08-17

  A-1331852 is a selective BCL-XL inhibitor for dissecting apoptosis, chemotherapy-induced senescence, and BCL-2 family protein inhibition. This guide focuses on experimental interpretation: how to distinguish target engagement from genuine BCL-XL dependence and design more informative apoptosis assays.

• Erastin and the Timing of Ferroptotic Stress

  2026-08-17

  Erastin offers a mechanistic route to study ferroptosis in RAS- and BRAF-altered tumor models. This thought-leadership guide connects cystine–glutathione failure with time-resolved oxidative-stress biology and translational experimental design.

• Mubritinib (TAK 165): A Metabolic Translation Playbook

  2026-08-16

  Mubritinib is best understood not as a conventional HER2 agent, but as a context-selective mitochondrial complex I inhibitor. This thought-leadership guide connects its AML and KSHV-positive PEL activity with assay design, formulation-aware translation, and a more disciplined strategy for cancer biology research.

• CD38 CAR Binder Structures and Affinity Tuning

  2026-08-15

  Cheng et al. structurally compared the CD38-targeting CAR binders RP02 and 028, showing that distinct epitope geometries govern antigen recognition, enzymatic inhibition, and cellular behavior. Their affinity-attenuated 028R103G design reduced CAR-T fratricide while preserving cytotoxicity, supporting structure-guided optimization rather than maximal-affinity selection.

• Ultrasound-Triggered Piezo-Nanoplatforms for Epilepsy

  2026-08-15

  The reference study develops a biomimetic piezoelectric nanoplatform that converts externally applied ultrasound into localized electrical stimulation for non-invasive neuromodulation. By combining ultrasound-responsive stimulation with antiepileptic drug delivery, the platform proposes a dual therapeutic strategy intended to improve seizure control while reducing reliance on implanted electrodes and systemic drug exposure.

• Nile Red in Laryngeal Cancer Lipid Biology

  2026-08-14

  Nile Red can convert lipid-droplet phenotypes into quantitative evidence for lipid metabolism research. This article connects Nile Red assay design with the THBS1 findings in laryngeal cancer while clarifying what fluorescence can—and cannot—establish about tumor biology.

• Flubendazole Workflows for Autophagy Research

  2026-08-14

  Flubendazole provides a practical DMSO-soluble perturbation tool for mapping autophagy responses in cancer biology research and metabolic stress models. This guide connects autophagy readouts with the glutamine-dependent hepatic stellate cell biology reported in a liver fibrosis study, while clearly separating established findings from hypothesis-driven assay design.

450 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page